NexGard (2 - 4 kg)
Active substance
ATC code
Species
Dogs.
Indications
Treatment of flea infestation in dogs (Ctenocephalides felis and C. canis). The veterinary medicinal product provides immediate and persistent killing activity for at least 5 weeks. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Treatment of tick infestation in dogs (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Hyalomma marginatum). The veterinary medicinal product provides immediate and persistent killing activity for one month.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
Treatment of demodicosis (caused by Demodex canis).
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis). Treatment of ear mite infestations (caused by Otodectes cynotis).
Dose to be administered and administration route
Oral use.
Dosage:
The veterinary medicinal product should be administered at a dose of 2.7 to 7 mg/kg bodyweight of afoxolaner in accordance with the following table:
|
Bodyweight of dog (kg) |
Strength and number of chewable tablets to be administered |
|||
|
NexGard 11 mg |
NexGard 28 mg |
NexGard 68 mg |
NexGard 136 mg |
|
|
2–4 |
1 |
|||
|
> 4–10 |
1 |
|||
|
> 10–25 |
1 |
|||
|
> 25–50 |
1 |
|||
For dogs above 50 kg bodyweight, use an appropriate combination of chewable tablets of different/same strengths.
To ensure a correct dosage, body weight should be determined as accurately as possible.
The chewable tablets should not be divided. Underdosing could result in ineffective use and may favour resistance development.
Method of administration:
The tablets are chewable and palatable to most dogs. If the dog does not accept the tablets directly they may be administered with food.
Treatment schedule:
Treatment of flea and tick infestations:
Monthly intervals throughout the flea and/or tick seasons, based on local epidemiological situations and the animal’s lifestyle.
Treatment of demodicosis (caused by Demodex canis):
Monthly administration of the veterinary medicinal product until two negative skin scrapings are obtained one month apart. Severe cases may require prolonged monthly treatments. As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis): Monthly administration of the veterinary medicinal product for two consecutive months. Further monthly administration may be required based on clinical assessment and skin scrapings.
Treatment of ear mite infestations (caused by Otodectes cynotis):
A single dose of the veterinary medicinal product should be administered. A further veterinary examination one month after the initial treatment is recommended as some animals may require a second treatment.
Adverse reactions
Dogs:
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Digestive tract disorders1(vomiting2, diarrhoea2) Lethargy2, anorexia2 Pruritus2 Neurological disorders (convulsion2, ataxia2, muscle tremor2). |
1 Mild.
2 Mostly self-limiting and of short duration.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Dispensing
POM-V - Prescription Only Medicine – Veterinarian
TRUSTED SOURCE
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 04491/5027 |
| EAN | 4028691568766 |
